Transplantation Market: Current Analysis and Forecast (2022-2030)

The transplantation market is expected to register a CAGR of approx. 9% over the period of 2022-2030. The transplantation market refers to the healthcare sector that encompasses the various aspects of organ and tissue transplantation procedures. It involves the procurement, preservation, transportation, and transplantation of organs, tissues, and cells from a donor to a recipient. The goal of transplantation is to replace a damaged or non-functioning organ or tissue with a healthy one, thereby restoring or improving the recipient's health and quality of life. The transplantation market includes a wide range of organ and tissue transplantations, such as heart, lung, liver, kidney, pancreas, cornea, bone marrow, and stem cell transplants. These procedures are performed to treat various conditions and diseases, including end-stage organ failure, certain cancers, genetic disorders, autoimmune diseases, and severe injuries. The growing demand for transplantations can be attributed to the high demand for tissue and organ transplantation, which includes organs such as kidneys, liver, heart, and lungs around the globe. For instance, an article published by Economic Times in March 2022 estimated that 220,000 patients require kidney transplantations annually in India. However, only 7,500 of these procedures are carried out. Owing to the glaring statistics the need for the organ is very high across the globe would contribute to the growth of the market in the forthcoming period as well. Furthermore, the transplantation market is anticipated to grow on account of continuous advancements in surgical techniques that have led to improved outcomes and success rates in transplantation procedures. Moreover, technological advancements in organ preservation have led to a growing demand for transplantations. However, some of the restraints in the market including organ rejection and immunological challenges are impeding the growth of this market all over the world.

Based on product, the market is segmented into tissue products, immunosuppressive drugs, and preservation solutions. Among them, the tissue products segment captured a significant share of the market in 2021. Tissue products, immunosuppressants, and preservation solutions are the most common products used in tissue or organ transplantation. The growing number of transplantation procedures, such as cochlear, heart valve, bone marrow, and orthopedic soft tissues, is related to the segment's expansion. Furthermore, new product development is supporting market expansion.

Based on the application, the market is bifurcated into organ transplantation and tissue transplantation. Among them, the tissue transplantation segment is expected to grow at a higher CAGR in the market. This is because skin, cornea, bones, heart valves, tendons, nerves, and veins replacement are the most regularly performed procedures worldwide. The increasing number of burn and injury cases is likely to drive tissue product demand.

Based on the end-user, the transplantation market has been classified into hospitals, transplantation centers, and others. Among them, the hospital category grabbed a considerable market share, and it is expected to grow at a significant CAGR during the forecast period. As primary care facilities, hospitals perform many organ and tissue transplant procedures. Furthermore, the introduction of hospitals with improved infrastructure is projected to drive market expansion. The majority of these hospitals have access to well-defined databases that allow them to check for the availability of organs, allowing for faster medical intervention.

For a better understanding of the market adoption of transplantation, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, France, Italy, Spain, U.K., and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of APAC), and Rest of World. North America, particularly the United States, is a hub for biotechnology and pharmaceutical research. The rising prevalence of chronic diseases, such as kidney disease, liver disease, and heart failure, is driving the demand for transplantation in North America. Companies in the region are focused on developing innovative transplantation solutions to meet this growing demand. For instance, in 2021, Medtronic, a leading medical technology company, announced the launch of the Medtronic Kidney Care Alliance. This alliance aims to address the growing burden of kidney disease and improve patient outcomes through a comprehensive approach that includes transplantation. Moreover, technological advancements in organ preservation methods have improved the transportation and storage of organs, leading to better transplantation outcomes. Companies in North America are investing in research and development of advanced organ preservation technologies. For instance, In 2021, TransMedics, a medical technology company, received FDA approval for its OCS Heart System. The system allows for the preservation and assessment of hearts for transplantation by providing a portable, warm perfusion environment that keeps the heart beating and functioning outside the body. Furthermore, precision medicine approaches, including genetic testing and personalized therapies, are gaining traction in transplantation. Companies are focusing on developing diagnostic tools and targeted therapies to improve patient outcomes and reduce organ rejection rates.

Some of the major players operating in Abbvie, Inc, Arthrex, Inc., Zimmer Biomet, Medtronic, Novartis AG, Strykers, F. Hoffmann-La Roche Ltd, BiolifeSolutions, Inc, Teva Pharmaceuticals, Veloxis Pharmaceutical among others. Several M&A's along with partnerships have been undertaken.